Navigation Links
Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
Date:6/24/2008

IRVINE, Calif., June 24 /PRNewswire/ -- Stason Pharmaceuticals, Inc., a vertically integrated cGMP contract development organization announced today that it has appointed Diana Wood as Vice President, Business Development. Ms. Wood will be responsible for all business development functions, including guiding Stason's global business development activities. Ms. Wood is a senior executive with extensive experience in sales, marketing, business and strategic planning, product development and general management on a worldwide basis. She will report directly to Chief Executive Officer Harry T. Fan. Most recently, Diana Wood served as the Executive Vice President, Business Development at Chiltern International, Inc., where she oversaw the company's global business development and marketing functions, and advised clients on their product development platforms. Prior to joining Chiltern International, Ms. Wood served as the Director, Product Development for Oncology at Chugai Pharma USA in San Diego.

"We are pleased to welcome Diana to Stason," said Mr. Fan. "As a seasoned business development executive, she has built a highly respected track record and earned the trust of the pharmaceutical community. Diana will be a strategically important asset to our company. Furthermore, by bringing an extensive knowledge of the pharmaceutical industry and its regulatory environment combined with confidence and multifaceted business experience, she will continue to broaden and strengthen our relationship with our drug development partners."

"I am delighted to join Stason, a fast-growing and forward thinking organization," Ms. Wood said. "Today's product development landscape is changing rapidly and paradigms are shifting towards a more technologically driven development process from the bench to market. Stason embraced these changes early on, reducing overall development time and costs. I look forward to bringing new opportunities to Stason and to further expand our global growth."

About Stason Pharmaceuticals:

Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution. Stason also out-licenses internally developed technologies to companies worldwide. Stason is specialized in developing and processing high-potency products, including oncology drugs.


'/>"/>
SOURCE Stason Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
2. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
3. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
4. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
5. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Medimetriks Pharmaceuticals, Inc. Begins Operations
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
8. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
10. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
11. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi AppTec, ... open-access capability and technology platform, today announced that ... biology focused preclinical drug discovery contract research organization ... become a wholly-owned subsidiary of WuXi, and will ... and providing greater services. The acquisition will further ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... Ca (PRWEB) , ... January 18, 2017 , ... ... events for tech innovators, engineers, and scientists from around the world, was today ... News. The awards program is based entirely on merit and decided upon by ...
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax┬« personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
Breaking Biology Technology:
(Date:1/18/2017)... Minn. , Jan. 18, 2017 ... technology company that supports the entire spectrum of ... has been another record-breaking year for the organization ... market interest in MedNet,s eClinical products and services. ... the tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... and Forecasts, 2015 - 2022," projects that the global biometric technology market is expected ... from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced today ... Life Alliance" established by iCarbonX, the ... build a "Global Digital Health Ecosystem that can ... combination of individual,s biological, behavioral and psychological data, ... between the companies, SomaLogic will provide proteomics data ...
Breaking Biology News(10 mins):